MetaCap

NRX Pharmaceuticals Inc. (NRXP)

NASDAQ: NRXPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.15-0.40 (-15.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NRXP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$95.31M
EPS (TTM)
-$0.33
52-week range
1.62 – 5.06
Day range
2.14 – 2.53
Volume / Avg
1.47M / 1.07M
Beta
—

52-week range

$1.62$5.06

NRXP stock today

Shares of NRX Pharmaceuticals (NRXP) finished lower on Nov 20 at $2.15, a drop of 15.69% or $0.40 per share, versus the S&P 500's 3.70% decline. At this level, NRXP sits near the bottom of its 52-week range of $1.62 to $5.06: 57.5% below the high, set on Jun 2, 2026 and 32.7% above the low. NRXP is down 20.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 0.9%.

NRX Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.33), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About NRX Pharmaceuticals

Company profile

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jonathan C. Javitt M.D., M.P.H.
Headquarters
Wilmington, DE
Employees
29
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, NRX Pharmaceuticals generated $1.2 million in revenue, up 0.0% from fiscal 2024. NRX Pharmaceuticals reported a net loss of $28.6 million, compared with a loss of $25.1 million a year earlier. Gross margin was 58.8% and operating margin -1324.4%.

NRX Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.23M$0$0——
Growth—————
Net income$-28.62M$-25.13M$-30.15M$-39.75M$-93.06M
EPS (diluted)———$-0.60$-1.98

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$38.75+1702.33%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $51.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.05 vs $-0.29
Surprise
+82.76%

NRXP news

All NRXP news

NRX Pharmaceuticals peers

Health Care sector
NRXP peer companies
CompanyPrice% ChgMarket capCompare
PDSBPDS Biotechnology Corporation0.7774-3.70%$95.39Mvs NRXP
NBPNovaBridge Biosciences ADR0.83-5.66%$96.28Mvs NRXP
DERMJourney Medical Corporation3.30-7.04%$93.16Mvs NRXP
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs NRXP
CLLSCellectis S.A. ADR0.9209-7.89%$92.76Mvs NRXP
CNTNCanton Strategic Holdings Inc.1.21-1.63%$98.78Mvs NRXP
CATXPerspective Therapeutics Inc.0.7538-3.85%$91.03Mvs NRXP
NERVMinerva Neurosciences Inc2.00-5.66%$99.67Mvs NRXP

Indexes, lists and sector

NRX Pharmaceuticals stock FAQ

What is NRX Pharmaceuticals's stock price today?

NRXP last traded at $2.15 as of Nov 20, 4:00 PM EST, down 15.69% on the day. Prices are delayed at least 15 minutes.

Does NRX Pharmaceuticals pay a dividend?

No. NRX Pharmaceuticals does not currently pay a regular cash dividend.

Who is NRX Pharmaceuticals's CEO?

Dr. Jonathan C. Javitt M.D., M.P.H. is the chief executive officer of NRX Pharmaceuticals Inc., which has about 29 employees.

Has NRXP ever split its stock?

Yes. The most recent NRXP stock split was a 1-for-10 split on Apr 2, 2024.

What is the NRXP 52-week high?

The 52-week high for NRXP is $5.06 and the 52-week low is $1.62. The stock is currently 57.5% below its high.

Compare NRXP